Markets

NovoCure slashes range and removes insider selling ahead of $176 million IPO

NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, slashed its range and removed insider selling ahead of its upcoming IPO on Thursday.

The St Helier, Jersey-based company now plans to raise $176 million by offering 7.5 million shares at a price range of $23 to $24. The company had previously filed to offer 12.5 million shares (5 million insider) at a range of $26 to $29. At the midpoint of the revised range, the IPO will raise 49% less in proceeds than previously anticipated.

NovoCure, which was founded in 2000 and booked $20 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol NVCR. J.P. Morgan, Deutsche Bank and Evercore Partners are the joint bookrunners on the deal. It is expected to price this week.

The article NovoCure slashes range and removes insider selling ahead of $176 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NVCR NVRO

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More